Evicenter
P&T meetings

Tovecimig (CTX-009)

Second-line advanced biliary tract cancer

Also known as ABL001
Last updated
89 sources

Economic information and modeling reportBudget impact model

Perspective and time frame

1 evidence topic · 3 sources

Budget impact model of tovecimig: perspective and time frame

No evidence found.

Perspectives and time horizons used in economic evaluations of advanced biliary tract cancer

“Most cost-effectiveness studies adopted a healthcare-payer or healthcare-system perspective, while only a minority explicitly incorporated broader societal costs such as productivity loss.” (opens the source at this quote in a new tab)

“Hence, with reference to the dosing cycle of the TOPAZ-1 clinical trial, we set the cycle of the Markov model to 21 days and the time horizon of 10 years to simulate the entire life course of the patient” (opens the source at this quote in a new tab)

“This research was based on the perspective of Chinese and US payers, applying discount rates of 3% and 5% to costs and utilities, respectively” (opens the source at this quote in a new tab)

“This analysis adopted the health care perspectives of third-party payers in China and the US, respectively.” (opens the source at this quote in a new tab)

“In China, costs (converted to US dollars) and utilities were discounted at 5%, whereas in the United States, both costs and utilities were discounted at 3%” (opens the source at this quote in a new tab)